IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is set to release its quarterly earnings with an expected EPS of -$0.67 and revenue of $2.5 million.
The company reported a larger-than-expected loss in the previous quarter, with an EPS of -$1.49, resulting in a negative surprise of 122.39%.
Despite financial challenges, including a negative P/E ratio of -10.16 and a high price-to-sales ratio of 462.67, IDYA maintains a strong current ratio of 22.93, indicating good short-term liquidity.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a company in the biomedical and genetics industry, focusing on developing innovative therapies for cancer treatment. Despite its promising research, IDYA faces financial challenges, as seen in its recent earnings reports. The company competes with other biotech firms in a highly competitive market, where financial performance is closely watched by investors.
On February 18, 2025, IDYA is set to release its quarterly earnings. Analysts expect an earnings per share (EPS) of -$0.67 and revenue of $2.5 million. However, in the previous quarter, IDYA reported a larger-than-expected loss of $1.49 per share, missing the Zacks Consensus Estimate by a significant margin. This resulted in a negative surprise of 122.39%.
The company’s financial performance has been inconsistent. In the last quarter, IDYA’s revenue was $7 million, matching the Zacks Consensus Estimate. This was an improvement from $3.92 million a year ago. Despite this growth, IDYA has not exceeded revenue estimates in the past four quarters, highlighting ongoing challenges in meeting market expectations.
IDYA’s financial ratios reflect its current struggles. The negative price-to-earnings (P/E) ratio of -10.16 indicates a lack of profitability. The high price-to-sales ratio of 462.67 suggests investors are paying a premium for each dollar of sales. Additionally, the enterprise value to sales ratio of 365.43 and the negative earnings yield of -9.84% further emphasize the company’s financial difficulties.
Despite these challenges, IDYA maintains a strong current ratio of 22.93, indicating excellent short-term liquidity. The low debt-to-equity ratio of 0.016 shows minimal reliance on debt financing. These factors suggest that while IDYA faces profitability issues, it has the financial stability to cover its short-term obligations.